Gloom Amidst Contract Research Boom
This article was originally published in PharmAsia News
Executive Summary
According to conservative estimates, China's contract research organization market has hit 4 billion yuan and is expanding at 100 percent annually. However, the breakneck development is curtailed by the shortage of talent with practical experience, high investments in research facilities, and ignorance on intellectual property rights. Industry experts suggest that domestic CROs can succeed only when they ensure international-level education and training, proper legal structure, and focused marketing development. They should also form a more competitive local team and concentrate on early stage drug development, as well as preclinical and Phase I and II clinical trials to take advantage of domestic resources. (Click here for more)